12:00 AM
 | 
Jul 28, 2014
 |  BC Week In Review  |  Clinical News  |  Regulatory

CRS-207 regulatory update

Aduro said FDA granted breakthrough therapy designation to the combination of CRS-207 and GVAX Pancreas cancer vaccine to treat pancreatic cancer. The designation was based on data from a Phase II trial of the combination in metastatic pancreatic cancer patients. Last year, Aduro reported that CRS-207 plus GVAX Pancreas and cyclophosphamide met the...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >